It is currently being evaluated in phase I/II trials of patients with unresectable or metastatic CCA and solid tumors harboring FGFR2 gene fusion, mutation, or amplification in the REFOCUS trial (NCT04526106). Here, FGFR2 is linked to cholangiocarcinoma.